Research Perspectives: A New Era in Idiopathic Pulmonary Fibrosis
The following articles were curated from a literature search of all recent publications on idiopathic pulmonary fibrosis (IPF). These studies highlight how biomarkers and signs of disease pathogenesis could facilitate more efficient and accurate diagnosis, and serve as future therapeutic targets and markers of therapeutic efficacy.
Pulmonologist Harold Collard, MD, Associate Professor of Medicine in the Division of Pulmonary and Critical Care Medicine and the Director of the Interstitial Lung Disease Program at the University of California, San Francisco, provides his perspective on 5 of the most recent studies on the pathology, diagnosis, and risk assessment of IPF.
Pulmonologists and other clinicians involved in the diagnosis and management of idiopathic pulmonary fibrosis
At the conclusion of this activity, participants should be better able to:
- Summarize the latest research developments in the field of idiopathic pulmonary fibrosis
- Incorporate evidence-based research into clinical practice
You may participate by listening to any—or all—of the audio discussions. Click the ‘Play’ button to hear our faculty perspectives on selected articles. Two questions will appear at the end of each discussion. When ready to claim your CME credit, click on and complete the “Program Evaluation” first (required) and then click on the “Certificate” to receive your certificate.
This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Supported by an educational grant from Genentech.
- 1.25 AMA PRA Category 1 Credit(s)™
- 1.25 Attendance